Among the combinations tested, dual inhibition of MEK and mTORC1/2 emerged as the most effective strategy for suppressing RAS signaling in MPNST cell lines, suggesting this combination may offer clinical benefit for NF1 patients with MPNSTs [123]. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.